~~<i id='555CB2657A'><strike id='555CB2657A'><tt id='555CB2657A'><pre id='555CB2657A'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：leisure time 2025-09-28 15:19:57 Page View：4269

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： David Sabatini, ex
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

focus

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

DarronCummings/APEliLillysaidFridaythatitwillacquireDermira,asmallbiotechdevelopingdrugsforchronicsk

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Websites selling Wegovy, Zepbound ingredients targeted by FDA

SarahSilbiger/GettyImagesTheFoodandDrugAdministrationiscrackingdownonwebsitesthatclaimtoselltheunder